PB2 Real-World Adherence to Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy Among Asthma Patients in the US

2021 ◽  
Vol 24 ◽  
pp. S13
Author(s):  
C. Averell ◽  
G. Germain ◽  
F. Laliberte ◽  
S. MacKnight ◽  
Y. Jung ◽  
...  
Keyword(s):  
Triple Therapy ◽  
Real World ◽  
Fluticasone Furoate ◽  
The Us ◽  
Asthma Patients

scholarly journals Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD

2021 ◽  
Vol 31 (1) ◽  
Author(s):  
Sandeep Bansal ◽  
Martin Anderson ◽  
Antonio Anzueto ◽  
Nicola Brown ◽  
Chris Compton ◽  
...  
Keyword(s):  
Health Status ◽  
Triple Therapy ◽  
Treatment Guidelines ◽  
Forced Expiratory Volume ◽  
Chronic Obstructive ◽  
Fluticasone Furoate ◽  
Double Blind ◽  
Once Daily ◽  
Copd Patients ◽  
Severe Copd

AbstractChronic obstructive pulmonary disease (COPD) treatment guidelines do not currently include recommendations for escalation directly from monotherapy to triple therapy. This 12-week, double-blind, double-dummy study randomized 800 symptomatic moderate-to-very-severe COPD patients receiving tiotropium (TIO) for ≥3 months to once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 mcg via ELLIPTA (n = 400) or TIO 18 mcg via HandiHaler (n = 400) plus matched placebo. Study endpoints included change from baseline in trough forced expiratory volume in 1 s (FEV1) at Days 85 (primary), 28 and 84 (secondary), health status (St George’s Respiratory Questionnaire [SGRQ] and COPD Assessment Test [CAT]) and safety. FF/UMEC/VI significantly improved trough FEV1 at all timepoints (Day 85 treatment difference [95% CI] 95 mL [62–128]; P < 0.001), and significantly improved SGRQ and CAT versus TIO. Treatment safety profiles were similar. Once-daily single-inhaler FF/UMEC/VI significantly improved lung function and health status versus once-daily TIO in symptomatic moderate-to-very-severe COPD patients, with a similar safety profile.

Commentary: real-world triple therapy experience treating hepatitis C virus

2014 ◽  
Vol 39 (5) ◽  
pp. 542-542 ◽  
Author(s):  
T. Heron ◽  
M. H. Miller ◽  
J. F. Dillon
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Triple Therapy ◽  
Real World

scholarly journals Exploring the Real-World Profile of Refractory and Non-Refractory Chronic Idiopathic Urticaria Patients in the US

2016 ◽  
Vol 137 (2) ◽  
pp. AB242
Author(s):  
Susan Gabriel ◽  
Meryl Mendelson ◽  
Alexander J. Gillespie ◽  
Ben Hoskin
Keyword(s):  
Real World ◽  
Chronic Idiopathic Urticaria ◽  
The Real ◽  
The Us
Sign in / Sign up

Export Citation Format

Share Document